Research press release


Nature Biotechnology

Stem cell therapy helps correct heart failure in monkeys



Charles Murryたちは、サルに心臓発作を起こさせて心臓の拍出機能を40%以上低下させた後、このサルの心臓にヒトES細胞由来の心筋細胞を約7億5000万個注入した。この移植細胞は、損傷した心臓内にかなりの量の新しい筋肉を形成した。4週間後、治療を受けたサルでは、心臓発作で失われた拍出機能が3分の1程度回復した。12週間経過観察した2頭では、拍出機能は3分の2以上に回復した。これらの結果が今後の臨床試験で再現されれば、この方法は心不全の有効な再生治療法になるかもしれない。

Transplanting human cardiac muscle cells into monkeys with heart failure can substantially restore the pumping capacity of the animals’ injured hearts, reports a study published online this week in Nature Biotechnology. Demonstrating this benefit in monkeys is a step toward advancing this therapy, which is based on human embryonic stem cells, to clinical trials in human patients.

In an untreated heart attack, blocked blood flow to the heart leads to the death of heart muscle cells, scarring and heart failure, which is the inability to pump enough blood to meet the body’s needs. Various new strategies for correcting heart failure have been found to work well in mice, but have gone on to fail in human trials. Studies in larger animals - such as monkeys, which are physiologically closer to humans - are more likely to predict whether a given therapy will work in people.

Charles Murry and colleagues induced heart attacks in monkeys, decreasing the pumping capacity of their hearts by more than 40%. They then injected about 750 million cardiac muscle cells, derived from human embryonic stem cells, into the monkeys’ hearts. The transplanted cells formed substantial amounts of new muscle in the injured hearts. Four weeks later, the treated monkeys regained about one-third of the pumping ability lost as a result of the heart attack. In two animals followed for 12 weeks, more than two-thirds of pumping ability was restored. If these results are reproduced in future clinical trials, this approach could provide a regenerative therapy for heart failure.

doi: 10.1038/nbt.4162


メールマガジンリストの「Nature 関連誌今週のハイライト」にチェックをいれていただきますと、毎週各ジャーナルからの最新の「注目のハイライト」をまとめて皆様にお届けいたします。